Evaluation of novel compounds as anti-bacterial or anti-virulence agents
Frontiers in Cellular and Infection Microbiology · 06.03.2024 · 14
DOI: 10.3389/fcimb.2024.1370062 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 06.03.2024. Verfasst von Brankica Filipić und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia. Hauptthemen laut MEDLINE: Anti-Infective Agents, Bacterial Infections. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 188 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Antimicrobial resistance is a global threat, leading to an alarming increase in the prevalence of bacterial infections that can no longer be treated with available antibiotics. The World Health Organization estimates that by 2050 up to 10 million deaths per year could be associated with antimicrobial resistance, which would equal the annual number of cancer deaths worldwide. To overcome this emerging crisis, novel anti-bacterial compounds are urgently needed. There are two possible approaches in the fight against bacterial infections: a) targeting structures within bacterial cells, similar to existing antibiotics; and/or b) targeting virulence factors rather than bacterial growth. Here, for the first time, we provide a comprehensive overview of the key steps in the evaluation of potential new anti-bacterial and/or anti-virulence compounds. The methods described in this review include: a) in silico methods for the evaluation of novel compounds; b) anti-bacterial assays (MIC, MBC, Time-kill); b) anti-virulence assays (anti-biofilm, anti-quorum sensing, anti-adhesion); and c) evaluation of safety aspects (cytotoxicity assay and Ames test). Overall, we provide a detailed description of the methods that are an essential tool for chemists, computational chemists, microbiologists, and toxicologists in the evaluation of potential novel antimicrobial compounds. These methods are cost-effective and have high predictive value. They are widely used in preclinical studies to identify new molecular candidates, for further investigation in animal and human trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.
- Laboratory for Molecular Biology, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.
Zitieren
APA
Filipić, B., Ušjak, D., Rambaher, M. H., Oljacic, S., & Milenković, M. T. (2024). Evaluation of novel compounds as anti-bacterial or anti-virulence agents. Frontiers in Cellular and Infection Microbiology, 14. https://doi.org/10.3389/fcimb.2024.1370062
Vancouver
Filipić B, Ušjak D, Rambaher MH, Oljacic S, Milenković MT. Evaluation of novel compounds as anti-bacterial or anti-virulence agents. Frontiers in Cellular and Infection Microbiology. 2024;14. doi:10.3389/fcimb.2024.1370062
BibTeX
@article{Filipi2024,
author = {Filipić, Brankica and Ušjak, Dušan and Rambaher, Martina Hrast and Oljacic, Slavica and Milenković, Marina T},
title = {Evaluation of novel compounds as anti-bacterial or anti-virulence agents},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2024},
volume = {14},
doi = {10.3389/fcimb.2024.1370062}
}
EUVIMED